30/06/2008 (Agence Europe) - The European Medicines Agency, on Thursday 26 June, recommended updating the warnings in relation to the risk of pulmonary and cardiac fibrosis associated with the long-term use of several dopamine agonists: bromocriptine, cabergoline, dihydroergocryptine, lisuride and pergolide. The EMEA calls for doses to be reduced and for signs of fibrosis to be monitored by means of regular echocardiography. These medicines are widely used in the treatment of a number of...